Replies to post #67478 on Biotech Values

[DewDiligence]

>… in addition to better efficacy or tolerability, if a next generation protease inhibitor has a dosing advantage, and/or can work in future HCV cocktails with other polymerase/protease inhibitors, it will be adopted…<

Agreed. Roche clearly has the inside track with respect to such cocktails.


<font size=3><font color=red> “The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”